Enlivex

A clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™ for inflammatory diseases and operating a prediction markets treasury.

Health Tech & Life Sciences
Active
Public Ness Ziona, Israel Founded 2005
Last updated 2026-11-03
Total raised
$739.2M
Last: PIPE 2026-07
Stage
Public
Founded
2005
Headcount
35
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

Enlivex is a clinical-stage immunotherapy company focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company aims to treat life-threatening or debilitating diseases involving acute or chronic inflammation, such as sepsis and osteoarthritis. Enlivex also operates a prediction markets treasury strategy, anchoring its reserves in the RAIN token.

Funding history · 14 rounds · $739.2M total

14 events/rounds · $739.2M Total Funding: $630.0M in Private Equity, $73.1M in Public Equity, $28.0M in Debt
Mar 2026
Debt Financing $21.0M sec.gov ↗
Nov 2025
PIPE $212.0M medpath.com ↗
Nov 2025
Public Offering Undisclosed prior (startupim db)
★ Pontifaxand 3 more
May 2022
Grant $1.2M enlivex.com
Mar 2020
Public Offering $16.8M ortex.com
Feb 2020
Public Offering $8.0M ortex.com
Mar 2019
Public Offering $5.4M calcalistech.com
★ HBL-Hadasit Bio Holdings★ KIP Global Pharma Private Equity Fund
Apr 2018
Jul 2014
Public Offering $38.0M prior (startupim db)
May 2014
Convertible Debt $7.0M nocamels.com
★ 3 more★ Pontifax★ Hadasit Bio Holdingsand 3 more

Offices

Ness Ziona, Israel · HQ / main office

Q&A

What is Enlivex's primary focus?
Enlivex is a clinical-stage immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state for treating inflammatory diseases.
When was Enlivex founded and where is its headquarters located?
Enlivex was founded in 2005 and is headquartered in Ness Ziona, Israel.
What was Enlivex's most recent funding round?
Enlivex secured a PIPE round in July 2026, raising $400,000,000 from a single institutional investor.
How much debt financing did Enlivex secure in March 2026?
In March 2026, Enlivex secured $21,000,000 in debt financing.
What was the amount and lead investors of Enlivex's Public Offering in May 2024?
In May 2024, Enlivex completed a Public Offering of $5,000,000 with H.C. Wainwright & Co. and a single healthcare-focused institutional investor.
Who are the co-founders of Enlivex?
The co-founders of Enlivex are Prof. Dror Mevorach and Shai Novik.
What is the total amount of funding Enlivex has raised to date?
Enlivex has raised a total of $739,210,000 to date.

Team · 10

Prof. Dror Mevorach
Founder · Co-Founder & Scientific Advisor
Shai Novik
Founder · Co-founder and Executive Chairman of the Board
Oren Hershkovitz
Chief Executive Officer
Shachar Shlosberger
Chief Financial Officer
Einat Galamidi
Chief Medical Officer
Shai Novik
Executive Chairman of the Board
Roger James Pomerantz
Independent Vice Chairman of the Board
Abraham Havron
Independent Director
Gili Hart
Independent Director
Matteo Renzi
Director

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies

Highlights

Patents

Tags

biotechnologyhealth-techlife-sciencesimmunotherapycell-therapymacrophage-reprogrammingosteoarthritissepsis
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteenlivex.com

Identifiers & details

Legal nameEnlivex Ltd.
Founded2005
Employees (exact)35

Radar intelligence

Patents

EPO22

Web history (Wayback)

Domainenlivex.com

Certificate / subdomain footprint

Subdomains17

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)513736264
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2005-09-25
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens0
Registry events1 — people (1)
Registered addressאינשטיין 14 נס ציונה

Recent registry events

DateEvent
2025-10-30עדכון בעלי תפקידים